[Research progress in pharmacological effects of Erigeron breviscapus and its active ingredients for treatment of Alzheimer's disease]

Zhongguo Zhong Yao Za Zhi. 2020 Dec;45(23):5650-5657. doi: 10.19540/j.cnki.cjcmm.20200717.602.
[Article in Chinese]

Abstract

Alzheimer's disease(AD) is a neurodegenerative disease that has no effective drug to cure it. Studies in several AD models have shown that Erigeron breviscapus and its active ingredients(scutellarin and caffeoylquinic acid) could improve/enhance the learning and memory ability, and the mechanisms are associated with inhibiting amyloid β(Aβ) production, aggregation, fibrosis and Aβ neurotoxicity toxicity, regulating cholinergic nervous system, inhibiting oxidative stress and inflammation, inhibiting tau hyperphosphorylation, improving mitochondrial function, and resisting neuronal apoptosis. This article systematically reviewed the research progress of E. breviscapus and its active ingredients for treatment of AD in AD models, in the expectation of providing references for further development of E. breviscapus's medicinal potential.

Keywords: Alzheimer′s disease; Erigeron breviscapus; caffeoylquinic acid; pharmacological effects; scutellarin.

Publication types

  • Systematic Review

MeSH terms

  • Alzheimer Disease*
  • Amyloid beta-Peptides
  • Erigeron*
  • Humans
  • Neurodegenerative Diseases*

Substances

  • Amyloid beta-Peptides